Published • loading... • Updated
Eli Lilly's Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss - Eli Lilly (NYSE:LLY)
Lilly said the lower-dose regimens preserved prior weight-loss results in late-stage trials, with 221 participants in the study.
- On Tuesday, May 12, 2026, Eli Lilly announced detailed results from two late-phase clinical trials showing patients with obesity maintained weight loss long-term after switching to either daily oral Foundayo or lower-dose Zepbound.
- Obesity is a chronic disease requiring long-term treatment, and these trials addressed the persistent challenge of weight regain for patients who have previously achieved weight loss.
- Both Zepbound and Foundayo demonstrated safety profiles consistent with prior clinical data, providing patients with multiple treatment options to manage weight maintenance after the initial reduction period.
- Participants in both studies successfully maintained their prior weight loss, as continuing treatment with these medications helps prevent the weight regain often associated with stopping therapy.
- These findings offer a potential strategy for long-term health management, giving clinicians evidence that transitioning to maintenance doses can sustain results for those managing chronic obesity.
Insights by Ground AI
35 Articles
35 Articles
The Conway Daily Sun+31 Reposted by 31 other sources
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one year
Coverage Details
Total News Sources35
Leaning Left6Leaning Right3Center13Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 27%
C 59%
14%
Factuality
To view factuality data please Upgrade to Premium
